[6-K] OKYO Pharma Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

OKYO Pharma (OKYO) reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 82,018 of the company’s ordinary shares on NASDAQ on November 21, 2025.

This additional purchase increases Cerrone’s total beneficial holding to 10,464,695 shares. The disclosure is informational in nature and does not change the company’s capital structure or operations, but it highlights further share accumulation by a key insider.

Insights

Equity analyst

OKYO’s executive chairman modestly increased his already large shareholding.

OKYO Pharma disclosed that Panetta Partners Limited, linked to Executive Chairman Gabriele Cerrone, bought 82,018 ordinary shares on NASDAQ. This takes his beneficial stake to 10,464,695 shares. The transaction represents incremental insider buying rather than a change to the company’s capital structure.

Because this is an open-market purchase by an existing large holder, it does not introduce new dilution or financing. The main relevance is governance and alignment, as it confirms continued exposure of the executive chairman to OKYO’s share price performance, based on the numbers reported as of November 21, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 2025

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 21, 2025, OKYO Pharma LTD (the “Company”) issued this 6K announcing, that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,464,695 shares.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: November 21, 2025	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated November 21, 2025

4

FAQ

What did OKYO Pharma (OKYO) announce in this Form 6-K?

OKYO Pharma announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 82,018 ordinary shares on NASDAQ on November 21, 2025.

How many OKYO Pharma shares does Gabriele Cerrone now beneficially hold?

Following the latest NASDAQ purchase, Gabriele Cerrone’s beneficial holding in OKYO Pharma increased to 10,464,695 ordinary shares.

Does this Form 6-K for OKYO involve a new share issuance or capital raise?

No. The filing describes an open-market purchase of OKYO Pharma’s existing ordinary shares by Panetta Partners Limited and does not indicate a new share issuance or capital raise.

Who executed the share purchase reported by OKYO Pharma?

The purchase of 82,018 ordinary shares was executed by Panetta Partners Limited, an entity in which OKYO’s Executive Chairman, Gabriele Cerrone, has a beneficial interest.

What exhibit accompanies this OKYO Pharma Form 6-K filing?

The filing includes Exhibit 99.1, described as a News Announcement dated November 21, 2025, which provides the related public announcement of the transaction.

Does the OKYO Pharma Form 6-K state that the information is filed or furnished?

The Form 6-K specifies that the information in Exhibit 99.1 is being furnished and is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.